Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Investment Securities: 2011-2023

Historic Gains from Investment Securities for Adma Biologics (ADMA) over the last 10 years, with Dec 2023 value amounting to $17,000.

  • Adma Biologics' Gains from Investment Securities was N/A to $1.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $17,000 for FY2023, which is 98.58% down from last year.
  • According to the latest figures from FY2023, Adma Biologics' Gains from Investment Securities is $17,000, which was down 98.58% from $1.2 million recorded in FY2022.
  • In the past 5 years, Adma Biologics' Gains from Investment Securities ranged from a high of $1.9 million in FY2021 and a low of $17,000 during FY2023.
  • For the 3-year period, Adma Biologics' Gains from Investment Securities averaged around $1.0 million, with its median value being $1.2 million (2022).
  • Per our database at Business Quant, Adma Biologics' Gains from Investment Securities rose by 29.09% in 2021 and then crashed by 98.58% in 2023.
  • Yearly analysis of 4 years shows Adma Biologics' Gains from Investment Securities stood at $1.5 million in 2020, then rose by 29.09% to $1.9 million in 2021, then tumbled by 37.01% to $1.2 million in 2022, then plummeted by 98.58% to $17,000 in 2023.